Literature DB >> 31161359

Uncommon Peptide Bond Cleavage of Glucagon from a Specific Vendor under near Neutral to Basic Conditions.

Hong-Jian Zheng1, Bin-Bin Shen1, Jing Wang1, Haibin Wang2, Guo-Li Huo1, Li-Rui Huang3, Jian-Qing Gao4, Wei-Jie Fang5.   

Abstract

PURPOSE: The main purposes of this manuscript are to report a surprising and interesting degradation reaction of glucagon from a specific vendor in which glucagon underwent cleavage among several peptide bonds quickly under near neutral to basic conditions, and to propose the root cause of mechanism for the degradation reaction.
METHODS: The degradation reaction was monitored by HPLC and the fragment structures were confirmed by LC-MS. Possible impurities responsible for the degradation were either confirmed or excluded by a variety of techniques such as addition of chelator EDTA and transitional metal ions or separation by ultrafiltration.
RESULTS: This type of degradation was rarely reported in literature, especially considering its extreme cleavage efficiency. Contamination by a thermostable high molecular impurity (such as a peptidase with molecular weight between 10 and 30 KDa) during the manufacturing process was the main reason for this interesting phenomenon.
CONCLUSIONS: The degradation phenomenon described here could be used as an excellent example showing that products ordered from vendors meeting the rudimentary quality standards might contain impurities which could cause significant degradation. We suggest that a simple solution, i.e. additional tests of stability under real or accelerated conditions by manufacturers and inclusion of the "accelerated stability criteria" in the Certificate of Analysis (CoAs), especially for sensitive biological reagents prone to faster degradation, would be very helpful for avoiding losses for both vendors and users.

Entities:  

Keywords:  Degradation products; LC-MS; glucagon; hydrolysis; peptide stability

Mesh:

Substances:

Year:  2019        PMID: 31161359     DOI: 10.1007/s11095-019-2647-y

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  18 in total

1.  The relative rates of glutamine and asparagine deamidation in glucagon fragment 22-29 under acidic conditions.

Authors:  Anjali B Joshi; Lee E Kirsch
Journal:  J Pharm Sci       Date:  2002-11       Impact factor: 3.534

2.  Effects of excipients on the chemical and physical stability of glucagon during freeze-drying and storage in dried formulations.

Authors:  Wei-Jie Fang; Wei Qi; John Kinzell; Steven Prestrelski; John F Carpenter
Journal:  Pharm Res       Date:  2012-07-06       Impact factor: 4.200

3.  Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature.

Authors:  Hongcheng Liu; Georgeen Gaza-Bulseco; Joanne Sun
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-04-27       Impact factor: 3.205

Review 4.  Fragmentation of monoclonal antibodies.

Authors:  Josef Vlasak; Roxana Ionescu
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

5.  Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity.

Authors:  Sharon X Gao; Ying Zhang; Kensey Stansberry-Perkins; Alex Buko; Shujun Bai; Vanessa Nguyen; Mark L Brader
Journal:  Biotechnol Bioeng       Date:  2010-11-17       Impact factor: 4.530

6.  Mechanisms of glucagon degradation at alkaline pH.

Authors:  Nicholas Caputo; Jessica R Castle; Colin P Bergstrom; Julie M Carroll; Parkash A Bakhtiani; Melanie A Jackson; Charles T Roberts; Larry L David; W Kenneth Ward
Journal:  Peptides       Date:  2013-05-04       Impact factor: 3.750

7.  Metal ion interactions with mAbs: Part 1.

Authors:  Zephania Kwong Glover; Louisette Basa; Benjamin Moore; Jennifer S Laurence; Alavattam Sreedhara
Journal:  MAbs       Date:  2015       Impact factor: 5.857

8.  Kinetics and Characterization of Non-enzymatic Fragmentation of Monoclonal Antibody Therapeutics.

Authors:  Sahithi Ravuluri; Rohit Bansal; Nidhi Chhabra; Anurag S Rathore
Journal:  Pharm Res       Date:  2018-05-14       Impact factor: 4.200

9.  Fragmentation of a recombinant monoclonal antibody at various pH.

Authors:  Georgeen Gaza-Bulseco; Hongcheng Liu
Journal:  Pharm Res       Date:  2008-05-13       Impact factor: 4.200

10.  The estimation of glutaminyl deamidation and aspartyl cleavage rates in glucagon.

Authors:  Anjali B Joshi; Lee E Kirsch
Journal:  Int J Pharm       Date:  2004-04-01       Impact factor: 5.875

View more
  1 in total

1.  Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models.

Authors:  Zhenhong Fu; David Mui; Hang Zhu; Ying Zhang
Journal:  Aging (Albany NY)       Date:  2020-05-11       Impact factor: 5.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.